{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:ema.enhertu:4 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Aema.enhertu%3A4",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.003891,
    "timestamp_received": "2026-04-24T03:20:25.444226+00:00Z",
    "timestamp_returned": "2026-04-24T03:20:25.448117+00:00Z",
    "trace_id": "73225c66-2b56-45d8-b0e4-08419362081b"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-04-09"
  },
  "data": [
    {
      "id": "ind:ema.enhertu:4",
      "indication": "Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.",
      "initial_approval_date": "2025-04-28",
      "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/enhertu-h-c-005124-ii-0048-epar-assessment-report-variation_en.pdf",
      "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regime.",
      "raw_biomarkers": "Hormone receptor (HR)-positive, HER2-low or HER2-ultralow",
      "raw_cancer_type": "breast cancer",
      "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:ema.enhertu",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.",
        "title": null,
        "aliases": [],
        "description": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.",
        "urls": [
          "https://www.ema.europa.eu/en/medicines/human/EPAR/enhertu",
          "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "ema",
              "type": "Agent",
              "agentType": "organization",
              "name": "European Medicines Agency",
              "description": "Regulatory agency that approves medicines for use in the European Union.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-10-01",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://www.ema.europa.eu/en/medicines",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "Daiichi Sankyo Europe GmbH.",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": "Enhertu",
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": "trastuzumab deruxtecan",
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": "2021-02-08",
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2025-04-28",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}